NSF International, a global public health and safety organization, has appointed Lynne Byers as executive director and David Waddington as director of NSF’s pharma biotech services in Europe.

 

Lynne Byers brings more than 35 years of extensive pharmaceutical manufacturing management and quality assurance (QA) experience to NSF International’s pharma biotech business. In her role, she will oversee consulting, auditing, and training services for a variety of pharmaceutical operations in Europe. She also provides strategic consulting and training services and assists clients in establishing and implementing remediation plans to address audit findings and regulatory actions.

Prior to joining NSF International, she was the Global Head (VP) of External Supply Operations QA for Novartis in Switzerland.

 

David Waddington comes to NSF International’s pharma biotech team with over 30 years of experience in a variety of roles for three major international pharmaceutical organizations. In his new position, his responsibilities will include the establishment, promotion and growth of NSF International’s consulting, auditing and training services in Europe. In addition, he is the key account manager in the development and maintenance of business relationships.

His most recent appointment prior to NSF International was Quality Director, Global Regulatory Compliance for Catalent Pharma Solutions. 

 

“Our group is very team-focused and it is a pleasure to welcome Lynne and David to the team. In just a few weeks they have settled in brilliantly and are already working with key clients to protect patients and businesses worldwide.” said Mike Halliday, executive vice president of Pharma Biotech, NSF International.